Cepheid is developing a rapid test, known as Xpert Carba-R, for detecting multidrug-resistant pathogens. The test has several advantages over existing diagnostic methods. The company successfully ...

Rapid diagnosis of TB is vital in areas such as sub-Saharan Africa and Southeast Asia due to the close connection between HIV and TB. Sputum microscopy, which often delivers poor sensitivity in ...

(RTTNews) - Cepheid, a unit of Danaher Corp. (DHR), said Thursday that it has received a medical device license from Health Canada for Xpert Xpress SARS-CoV-2/Flu/RSV, a rapid molecular diagnostic ...

The all-cash deal will expand Danaher's already hefty life sciences division. D.C.-based Danaher Corp. (NYSE: DHR) is buying California molecular diagnostics company Cepheid Inc. (NASDAQ: CPHD) for ...

(Reuters) - Molecular diagnostics company Cepheid said it received a grant of up to $3.3 million, co-financed by the Paul G. Allen Family Foundation and the Bill & Melinda Gates Foundation, to develop ...

Cepheid said it will partner with MedImmune and a European public/private partnership that promotes anti-infective drug development to develop rapid diagnostic tests in respiratory secretions of ...

On Aug 8, we issued an updated research report on Cepheid ( CPHD). The company recently reported better-than-expected second-quarter 2014 results with narrower loss than the Zacks Consensus Estimate ...

Danaher Corp. said Monday it has agreed to acquire diagnostics company Cepheid for $53 a share in cash or about $4 billion. Danaher said it expects to finance the deal with cash and debt. Cepheid had ...

A controversy has broken out over a diagnostic for tuberculosis that, until recently, had been subsidized by the World Health Organization — the latest flare-up over access to a medical product in ...

For much of last year, the coronavirus crept, undetected, across eastern Democratic Republic of Congo. Test samples had to be sent more than 1,500 kilometres from remote hospitals to the capital ...

Danaher Corp. said Monday it has agreed to acquire diagnostics company Cepheid for $53 a share in cash or about $4 billion. Danaher said it expects to finance the deal with cash and debt. Cepheid had ...

Science, health care and technology conglomerate Danaher Corp.DHR-1.46%decrease; red down pointing triangle said Tuesday that it would buy molecular-diagnostics company Cepheid Inc. for $53.00 a share ...